Bristol Myers Squibb is a Princeton, New Jersey-based, NYSE-listed (ticker: BMY) global biopharmaceutical company that discovers, develops, manufactures, and commercialises medicines for serious diseases, with a portfolio organised around a "Growth Portfolio" (Opdivo, Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Yervoy, Orencia, Zeposia, Sotyktu, Krazati, Cobenfy) and a "Legacy Portfolio" (Eliquis, Revlimid, Pomalyst, Sprycel, Abraxane) that is exposed to the loss-of-exclusivity (LOE) cycle for Revlimid and Pomalyst. The Q2 2026 print shows a business that is, in our view, executing on the late-cycle LOE transition: total revenues of $13.0 billion (+6% YoY, +5% Ex-FX), Growth Portfolio revenues of $7.6 billion (+15% YoY, +14% Ex-FX), GAAP EPS of $1.62, non-GAAP EPS of $2.04, and an upward revision to the full-year 2026 guidance (revenue range raised to $49.0-50.0 billion, non-GAAP EPS range raised to $6.75-7.00). The investment case is a debate about whether the Growth Portfolio can sustain 15%+ growth through 2027-2028 to offset the continued Revlimid/Pomalyst LOE drag and to support the next phase of the equity story.
The strategic positioning of the company is, in our view, a real and meaningful late-cycle LOE transition. The Growth Portfolio of $7.6 billion in Q2 2026 (+15% YoY) is, in our view, the principal value driver, with the corresponding growth concentrated in Opdivo Qvantig (subcutaneous nivolumab, +200% growth in the first full launch quarter), Reblozyl (+29% YoY), Camzyos (+59% YoY), Breyanzi (+41% YoY), and Opdualag (+23% YoY). The Legacy Portfolio of $5.4 billion in Q2 2026 (-4% YoY, -5% Ex-FX) is, in our view, the principal drag, with the corresponding decline concentrated in Revlimid (-49% YoY) and Pomalyst (-71% YoY), partially offset by Eliquis growth (+22% YoY). The bull case is that the Growth Portfolio can sustain 15%+ growth through 2027-2028 to offset the LOE drag, the late-stage pipeline (milvexian, ianalumab, the Karuna-Cerevel integration) is a real and meaningful long-duration value driver, and the corresponding operating-margin expansion is sustainable. The bear case is that the Growth Portfolio growth is approaching a maturation point, the LOE drag is more severe than the management team has communicated, the late-stage pipeline is less successful than the management team has communicated, and the corresponding operating-margin compression is more challenged than the Q2 print disclosed.
The most important event of the Q2 2026 print is the upward revision to the full-year 2026 guidance, with the revenue range raised to $49.0-50.0 billion and the non-GAAP EPS range raised to $6.75-7.00. The upward revision is, in our view, a meaningful positive signal that reflects the underlying operating performance, the Growth Portfolio momentum, and the corresponding confidence in the LOE transition. The implication is that the upward revision is, in our reading, a real and meaningful positive signal that supports the long-duration equity story, and the corresponding full-year 2026 trajectory is, in our view, modestly above the consensus expectations.
A second material event of the Q2 2026 print is the Growth Portfolio's +15% growth in Q2, which is, in our view, the principal value driver for the consolidated franchise. The Growth Portfolio growth is concentrated in the higher-margin newer launches (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag), and the corresponding revenue mix shift is, in our view, a real and meaningful positive signal that supports the long-duration operating-margin trajectory. The implication is that the Growth Portfolio momentum is, in our reading, a real and meaningful positive signal that supports the long-duration equity story.
A third material event of the Q2 2026 print is the Legacy Portfolio's -4% revenue decline in Q2, which is, in our view, the principal drag for the consolidated franchise. The Legacy Portfolio decline is concentrated in Revlimid (-49% YoY) and Pomalyst (-71% YoY), partially offset by Eliquis growth (+22% YoY). The implication is that the Legacy Portfolio decline is, in our reading, broadly in line with the management team's stated LOE transition trajectory, and the corresponding Eliquis growth is, in our view, a real and meaningful positive offset.
A fourth material event of the Q2 2026 print is the operational execution of the Karuna-Cerevel integration, which closed in March 2024 and added Cobenfy (xanomeline plus trospium) to the Growth Portfolio. Cobenfy revenue of $63 million in Q2 2026 (+81% YoY) is, in our view, a meaningful early-launch revenue line that supports the long-duration Growth Portfolio trajectory. The implication is that the Cobenfy integration is, in our reading, broadly on track, and the corresponding Cobenfy launch trajectory is, in our view, a real and meaningful positive signal that supports the long-duration Growth Portfolio trajectory.